Literature DB >> 11870154

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

Stephen A Cannistra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11870154     DOI： 10.1200/JCO.2002.20.5.1158

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

Review 1.  Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.

Authors:  Elena S Ratner; Alan C Sartorelli; Z Ping Lin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

2.  Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.

Authors:  Thapi D Rao; Nestor Rosales; David R Spriggs
Journal:  Mol Cancer Ther       Date:  2011-08-04       Impact factor: 6.261

3.  The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer.

Authors:  Yan Zhang; Qian Mei; Yang Liu; Xiang Li; Malcolm V Brock; Meixia Chen; Liang Dong; Lu Shi; Yao Wang; Mingzhou Guo; Jing Nie; Weidong Han
Journal:  Oncoimmunology       Date:  2017-05-17       Impact factor: 8.110

4.  Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

Authors:  Helen J Mackay; Hal Hirte; Terrence Colgan; Al Covens; Katrina MacAlpine; Pamela Grenci; Lisa Wang; Jaqueline Mason; Pnu-An Pham; Ming-S Tsao; James Pan; James Zwiebel; Amit M Oza
Journal:  Eur J Cancer       Date:  2010-03-19       Impact factor: 9.162

5.  The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.

Authors:  Lilian T Gien; Helen J Mackay
Journal:  J Oncol       Date:  2009-12-16       Impact factor: 4.375

6.  Bevacizumab in the treatment of ovarian cancer.

Authors:  Ramez N Eskander; Leslie M Randall
Journal:  Biologics       Date:  2011-01-11

Review 7.  Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.

Authors:  P A Vasey
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

8.  Emerging treatment options for management of malignant ascites in patients with ovarian cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Int J Womens Health       Date:  2012-08-03

9.  CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery.

Authors:  Fang Wang; Yanfen Ye; Xia Xu; Xuehui Zhou; Jinhua Wang; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2013-02-13       Impact factor: 4.234

10.  Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.

Authors:  G D'Agostino; G Ferrandina; M Ludovisi; A Testa; D Lorusso; N Gbaguidi; E Breda; S Mancuso; G Scambia
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.